CAPS Medical is a medical device company focused on the development and commercialization of its NTAP System, which uses non-thermal atmospheric plasma (NTAP) to treat a wide range of solid tumors. The minimally invasive and selective cancer treatment targets solid tumors and aims to selectively and precisely destroy only cancerous cells, leaving healthy tissue intact.
The company has obtained outstanding results from its first clinical study focusing on non-muscle invasive bladder cancer (NMIBC), the sixth most common cancer . Worldwide, more than 1.6 M people suffer from NMIBC, with around 200,000 new cases annually. In addition the company has demonstrated feasibility to enable the technology’s use for additional cancers including in lungs, esophagus, stomach ,GI and others.
Originally developed at the Technion - Israel Institute of Technology, the system is supported by key opinion leaders from medical fields such as oncology and interventional radiology. CAPS Medical has been supported by major shareholders and a strategic investo.